These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 33899554)

  • 1. Protective Effects of Extracellular Matrix-Derived Hydrogels in Idiopathic Pulmonary Fibrosis.
    Evangelista-Leite D; Carreira ACO; Gilpin SE; Miglino MA
    Tissue Eng Part B Rev; 2022 Jun; 28(3):517-530. PubMed ID: 33899554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three dimensional fibrotic extracellular matrix directs microenvironment fiber remodeling by fibroblasts.
    Nizamoglu M; Alleblas F; Koster T; Borghuis T; Vonk JM; Thomas MJ; White ES; Watson CK; Timens W; El Kasmi KC; Melgert BN; Heijink IH; Burgess JK
    Acta Biomater; 2024 Mar; 177():118-131. PubMed ID: 38350556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular mechanisms of extracellular matrix-derived hydrogel therapy in idiopathic pulmonary fibrosis models.
    Evangelista-Leite D; Carreira ACO; Nishiyama MY; Gilpin SE; Miglino MA
    Biomaterials; 2023 Nov; 302():122338. PubMed ID: 37820517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis.
    Tjin G; White ES; Faiz A; Sicard D; Tschumperlin DJ; Mahar A; Kable EPW; Burgess JK
    Dis Model Mech; 2017 Nov; 10(11):1301-1312. PubMed ID: 29125826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
    Epstein Shochet G; Wollin L; Shitrit D
    Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human lung extracellular matrix hydrogels resemble the stiffness and viscoelasticity of native lung tissue.
    de Hilster RHJ; Sharma PK; Jonker MR; White ES; Gercama EA; Roobeek M; Timens W; Harmsen MC; Hylkema MN; Burgess JK
    Am J Physiol Lung Cell Mol Physiol; 2020 Apr; 318(4):L698-L704. PubMed ID: 32048864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dicer1 Deficiency in the Idiopathic Pulmonary Fibrosis Fibroblastic Focus Promotes Fibrosis by Suppressing MicroRNA Biogenesis.
    Herrera J; Beisang DJ; Peterson M; Forster C; Gilbertsen A; Benyumov A; Smith K; Korenczuk CE; Barocas VH; Guenther K; Hite R; Zhang L; Henke CA; Bitterman PB
    Am J Respir Crit Care Med; 2018 Aug; 198(4):486-496. PubMed ID: 29579397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary matrix-derived hydrogels from patients with idiopathic pulmonary fibrosis induce a proinflammatory state in lung fibroblasts in vitro.
    Fernandez Davila JG; Singh AK; Moore DW; Kim J; Khan JA; Lemma M; King CS; Nathan SD; Rodriguez LR; Grant GM; Moran JL
    Mol Biol Cell; 2024 Aug; 35(8):ar114. PubMed ID: 38985514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
    Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
    Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung.
    Sava P; Ramanathan A; Dobronyi A; Peng X; Sun H; Ledesma-Mendoza A; Herzog EL; Gonzalez AL
    JCI Insight; 2017 Dec; 2(24):. PubMed ID: 29263297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis.
    Kliment CR; Oury TD
    Free Radic Biol Med; 2010 Sep; 49(5):707-17. PubMed ID: 20452419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteopontin: an essential regulatory protein in idiopathic pulmonary fibrosis.
    Zhu X; Ji J; Han X
    J Mol Histol; 2024 Feb; 55(1):1-13. PubMed ID: 37878112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.
    Ballester B; Milara J; Cortijo J
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30704051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiopathic pulmonary fibrosis: Current and future treatment.
    Glass DS; Grossfeld D; Renna HA; Agarwala P; Spiegler P; DeLeon J; Reiss AB
    Clin Respir J; 2022 Feb; 16(2):84-96. PubMed ID: 35001525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-fibrotic strategies and pulmonary fibrosis.
    Gunatilaka A; Zhang S; Tan WSD; G Stewart A
    Adv Pharmacol; 2023; 98():179-224. PubMed ID: 37524487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
    Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
    Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Klotho antagonizes pulmonary fibrosis through suppressing pulmonary fibroblasts activation, migration, and extracellular matrix production: a therapeutic implication for idiopathic pulmonary fibrosis.
    Huang Q; Chen Y; Shen S; Wang Y; Liu L; Wu S; Xu W; Zhao W; Lin M; Wu J
    Aging (Albany NY); 2020 Apr; 12(7):5812-5831. PubMed ID: 32244228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chondroitin sulfate in tissue remodeling: Therapeutic implications for pulmonary fibrosis.
    Kai Y; Yoneyama H; Yoshikawa M; Kimura H; Muro S
    Respir Investig; 2021 Sep; 59(5):576-588. PubMed ID: 34176780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A roadmap for developing and engineering
    Dabaghi M; Carpio MB; Saraei N; Moran-Mirabal JM; Kolb MR; Hirota JA
    Biophys Rev (Melville); 2023 Jun; 4(2):021302. PubMed ID: 38510343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.